MOLN - Molecular Partners AG Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Select Current Price & Safety Score Price: 3.71 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): -3.74 StockBond Score: -1.68 Company Description Molecular Partners AG operates as a clinicalstage biopharmaceutical company specializing in the identification advancement and commercialization of innovative therapeutic proteins The firms pipeline includes a range of product candidates many of which utilize its proprietary DARPinR technology Key developments include Abicipar a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet agerelated macular degeneration and diabetic macular edema In the infectious disease space they are advancing MP0420 a multispecific DARPin therapeutic targeting the SARSCoV2 virus and MP0423 for COVID19 treatment Their oncology programs feature MP0310 currently in Phase Ia clinical trials for immunooncology MP0317 a tumorlocalized immune agonist designed to stimulate immune cells within tumors which is undergoing Phase I clinical trials and MP0274 also in Phase I for HER2positive cancers Additional therapeutic candidates encompass MP0533 a CD3 T cell agent for acute myeloid leukemia and MP0250 engineered to extend drug halflife by interacting with vascular endothelial growth factor hepatocyte growth factor and human serum albumin Molecular Partners AG has established significant partnerships and collaboration agreements with various entities such as Novartis AG for the development manufacturing and commercialization of DARPinconjugated radioligand therapies Amgen SA Allergan Inc and a discovery alliance in ophthalmology with AbbVie Inc in addition to other thirdparty collaborators The company was incorporated in 2004 and is headquartered in Schlieren Switzerland